Drug Pricing: Manufacturer Discounts in the 340b Program Offer Benefits, But Federal Oversight Needs Improvement: Gao-11-836 (Paperback) (ISBN-13: 9781287207627)

The Health Resources and Services Administration (HRSA), within in the Department of Health and Human Services (HHS), oversees the 340B Drug Pricing Program, through which participating drug manufacturers give certain entities within the health care safety net--known as covered entities--access to discounted prices on outpatient drugs. Covered entities include specified federal grantees and hospitals. The number of covered entity sites has nearly doubled in the past 10 years to over 16,500. The Patient Protection and Affordable Care Act (PPACA) mandated that GAO address questions related to the 340B program. GAO examined: (1) the extent to which covered entities generate 340B revenue, factors that affect revenue generation, and how they use the program; (2) how manufacturers' distribution of drugs at 340B prices affects covered entities' or non-340B providers' access to drugs; and (3) HRSA's oversight of the 340B program. GAO reviewed key laws and guidance, analyzed relevant data, and conducted interviews with 61 340B program stakeholders selected to represent a range of perspectives, including HRSA, 29 covered entities, 10 manufacturers and representatives, and 21 others. Selection of stakeholders was judgmental and thus, responses are not generalizable.

Author: U. S. Government Accountability Office (
ISBN-10: 1287207626
ISBN-13: 9781287207627
Publisher: Bibliogov
Language: English
Published: 05/16/2013
Pages: 58
Format: Paperback
Weight: 0.27lbs
Size: 9.69h x 7.44w x 0.12d